PIRS Insider Trading Activity and SEC Form 4 Filings
PIRS insider trading summary
No open-market insider purchases or sales of Pieris Pharmaceuticals, Inc. (PIRS) have been reported on SEC Form 4 in the past 12 months.
Latest PIRS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 12, 2024 | ADAR1 Capital Management, LLC | 10% Owner | Buy | $36K (2,243 @ $15.88) |
| Aug 12, 2024 | ADAR1 Partners, LP | 10% Owner | Buy | $12K (757 @ $15.88) |
| Aug 12, 2024 | ADAR1 Partners, LP | 10% Owner | Buy | $36K (2,243 @ $15.88) |
| Aug 12, 2024 | ADAR1 Capital Management, LLC | 10% Owner | Buy | $12K (757 @ $15.88) |
| Aug 9, 2024 | ADAR1 Capital Management, LLC | 10% Owner | Buy | $45K (3,000 @ $14.89) |
| Aug 9, 2024 | ADAR1 Partners, LP | 10% Owner | Buy | $45K (3,000 @ $14.89) |
| Aug 7, 2024 | James A Geraghty | Director | Buy | $1 (1 @ $1.00) |
| May 25, 2023 | Christopher P Kiritsy | Insider | Buy | $9K (10,000 @ $0.85) |
| May 13, 2022 | Tim Demuth | Chief Medical Officer | Buy | $10K (6,000 @ $1.71) |
| Aug 30, 2021 | Shane Olwill | Chief Development Officer | Sell | $150K (29,200 @ $5.15) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.